Effects of Korean red ginseng (Panax Ginseng Meyer) on bisphenol A exposure and gynecologic complaints: single blind, randomized clinical trial of efficacy and safety. [ Free Full-text ]

Effects of Korean red ginseng (Panax Ginseng Meyer) on bisphenol A exposure and gynecologic complaints: single blind, randomized clinical trial of efficacy and safety.

BMC Complement Altern Med. 2014;14:265

Authors: Yang M, Lee HS, Hwang MW, Jin M

Abstract
BACKGROUND: Korean red ginseng (KRG) is a processed ginseng from raw ginseng to enhance safety, preservation and efficacy, known having beneficial effects on women’s health due to its estrogen like function. While estrogen supplementation showed some modulation of endocrine disrupting chemicals, bisphenol A (BPA) has been focused as a potential endocrine disrupting chemical. In this study, we examined the efficacy and safety outcomes of KRG against BPA, focusing on female quality of life (QOL). Individual variations in susceptibility to KRG were also investigated with the Sasang Typology, the personalized medicine used for hundred years in Korea.

METHODS: We performed a single-blind randomized clinical trial. Study subjects were young women (N = 22), consumed 2.7 g of KRG or placebo per day for 2 weeks and filled up questionnaires regarding gynecologic complaints at the 4 time spots. We analyzed urinary total BPA and malondialdehyde (MDA), an oxidative stress biomarker, with GC/MS and HPLC/UVD respectively, and diagnosed their Sasang Typology with the questionnaire for the Sasang constitution Classification (QSCC II).

RESULTS: KRG consumption decreased urinary BPA and MDA levels (ps < 0.05) and alleviated ‘menstrual irregularity’, ‘menstrual pain’, and ‘constipation’ (ps < 0.05). SoEum type (Lesser Yin person) among the Sasang types showed significant alleviation in insomnia, flushing, perspiration and appetite by KRG consumption, rather than other Sasang types. During the intervention, no one experienced any aggravated side effects.

CONCLUSION: We suggest KRG is efficient for protection for female QOL and BPA- exposure and – related oxidative stress. However, individual variation in susceptibility to KRG should be further considered for identifying ideal therapy.
TRIAL REGISTRATION: KCT0000920.

PMID: 25063041 [PubMed – indexed for MEDLINE]

Full-text Download Button